Overview

* Integra Q2 revenue of $415.6 mln beats analyst expectations, per LSEG data

* Adjusted EPS for Q2 at $0.45, exceeding analyst estimates, per LSEG data

* GAAP net loss driven by $511 mln goodwill impairment charge

Outlook

* Company expects Q3 revenue between $410 mln and $420 mln

* Integra Lifesciences ( IART ) sees Q3 adjusted EPS of $0.40 to $0.45

* Company updates full-year revenue guidance to $1.655 bln to $1.680 bln

* Integra reaffirms full-year adjusted EPS guidance of $2.19 to $2.29

Result Drivers

* GOODWILL IMPAIRMENT - $511 mln charge due to stock price drop from tariff changes and operational issues

* NEUROSURGERY DEMAND - Strong demand for neurosurgery products like CUSA and Aurora, offset by shipping holds

* SUPPLY CHAIN ISSUES - Private label sales down due to component supply delays and softer demand

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $415.60 $395.10

Revenue mln mln (10

Analysts

)

Q2 Beat $0.45 $0.43

Adjusted (10

EPS Analysts

)

Q2 EPS -$6.31

Q2 $34.40

Adjusted mln

Net

Income

Q2 $71.20

Adjusted mln

EBITDA

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 6 "hold" and 4 "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

* Wall Street's median 12-month price target for Integra Lifesciences Holdings Corp ( IART ) is $13.00, about 4.8% above its July 30 closing price of $12.37

* The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)